Vivos Therapeutics, Inc.

For Q2 2026, revenue increased about $1.3 million, or 35%, to $5.2 million from $3.8 million a year ago. For the first six months of 2026, revenue increased $3.5 million, or 51%, to $10.3 million from $6.8 million. Gross profit was $3 million in Q2, up $800,000, with gross margin at 57%; for the first half, gross profit was $6 million and gross margin was 58% versus 53% last year. The company reported a loss of $5.5 million for Q2 and $13.3 million for the first six months, versus losses of $5 million and $8.9 million in the prior-year periods. On cash and liquidity, Vivos ended June 30, 2026 with $1.8 million in cash and cash equivalents, $28.1 million in total liabilities, and $9.2 million of net cash used in operating activities for the first six months. Management said that cash will not be sufficient to fund operations and strategic objectives over the next 12 months without additional financing and that the company is not in compliance with Nasdaq minimum stockholders’ equity requirements. Looking ahead, management said two cardiology partnerships in Arizona and Florida would require $800,000 to $1 million of capex each and could begin generating revenue in Q1 to Q2 2027.

Kirk Huntsman framed SCN as a platform that is broader than a single acquisition, saying it creates a clinical system that can drive diagnostics, treatment, and recurring revenue. He emphasized several growth levers already underway: remote monitoring for CPAP patients, a planned wholly owned CPAP DME program, insomnia/EEG testing and treatment, pediatric OSA, and expanded capacity in Henderson. His tone was optimistic but qualified, repeatedly noting that the business is still early in these initiatives and that execution, reimbursement, staffing, and scaling will determine the outcome.

Bradford Amman said the pivot toward sleep centers is taking hold, with service revenue up $1.9 million in Q2 and $4.4 million in the first half, while product revenue fell as the company shifted away from VIPs. He noted higher costs tied to diagnostic services and patient therapy, including added staff, with cost of sales up 29% in Q2 to $2.2 million and up 33% year to date to $4.3 million. He also highlighted continued losses, an accumulated deficit of $138 million, $1.8 million in cash, and $0.5 million of net proceeds from 694,564 ATM shares sold at an average price of $0.69, with $2.3 million remaining available under the ATM.

Analysts focused on the capital needs and timing of the Arizona and Florida cardiology partnerships, and management said each would require $800,000 to $1 million of capex, with revenue expected in the first to second quarter of 2027. They also asked about the insomnia and EEG program; management said reimbursement is so far encouraging, with EEG testing reimbursing at around $800 per patient on average in Nevada, but treatment reimbursement is still early. Management said the program is already seeing payer participation and is becoming a meaningful growth driver.